Merck

Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.

Nature communications (2015-04-01)
Shahul Hameed P, Suresh Solapure, Vikas Patil, Philipp P Henrich, Pamela A Magistrado, Sowmya Bharath, Kannan Murugan, Pavithra Viswanath, Jayashree Puttur, Abhishek Srivastava, Eknath Bellale, Vijender Panduga, Gajanan Shanbag, Disha Awasthy, Sudhir Landge, Sapna Morayya, Krishna Koushik, Ramanatha Saralaya, Anandkumar Raichurkar, Nikhil Rautela, Nilanjana Roy Choudhury, Anisha Ambady, Radha Nandishaiah, Jitendar Reddy, K R Prabhakar, Sreenivasaiah Menasinakai, Suresh Rudrapatna, Monalisa Chatterji, María Belén Jiménez-Díaz, María Santos Martínez, Laura María Sanz, Olivia Coburn-Flynn, David A Fidock, Amanda K Lukens, Dyann F Wirth, Balachandra Bandodkar, Kakoli Mukherjee, Robert E McLaughlin, David Waterson, Lyn Rosenbrier-Ribeiro, Kevin Hickling, V Balasubramanian, Peter Warner, Vinayak Hosagrahara, Adam Dudley, Pravin S Iyer, Shridhar Narayanan, Stefan Kavanagh, Vasan K Sambandamurthy
RESUMO

The widespread emergence of Plasmodium falciparum (Pf) strains resistant to frontline agents has fuelled the search for fast-acting agents with novel mechanism of action. Here, we report the discovery and optimization of novel antimalarial compounds, the triaminopyrimidines (TAPs), which emerged from a phenotypic screen against the blood stages of Pf. The clinical candidate (compound 12) is efficacious in a mouse model of Pf malaria with an ED99 <30 mg kg(-1) and displays good in vivo safety margins in guinea pigs and rats. With a predicted half-life of 36 h in humans, a single dose of 260 mg might be sufficient to maintain therapeutic blood concentration for 4-5 days. Whole-genome sequencing of resistant mutants implicates the vacuolar ATP synthase as a genetic determinant of resistance to TAPs. Our studies highlight the potential of TAPs for single-dose treatment of Pf malaria in combination with other agents in clinical development.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Aluminum oxide, nanoparticles, <50 nm particle size (DLS), 20 wt. % in isopropanol
Sigma-Aldrich
Di-tert-butyl dicarbonate solution, 2 M in methylene chloride
Sigma-Aldrich
Di-tert-butyl dicarbonate solution, 2 M in THF
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
Sigma-Aldrich
Aluminum oxide, 99.997% trace metals basis
Sigma-Aldrich
Toluene, anhydrous, 99.8%
Sigma-Aldrich
2-Methylpyridine, 98%
Supelco
Aluminum oxide, for the determination of hydrocarbons
Sigma-Aldrich
Di-tert-butyl dicarbonate solution, 1.0 M in THF
Supelco
Hydrogen chloride – methanol solution, ~1.25 m HCl (T), for GC derivatization, LiChropur
Supelco
Aluminum oxide, activated, neutral, Brockmann Activity I
Supelco
Toluene, analytical standard
Sigma-Aldrich
N,N-Diisopropylethylamine, purified by redistillation, 99.5%
Sigma-Aldrich
Aluminum oxide, nanowires, diam. × L 2-6 nm × 200-400 nm
Sigma-Aldrich
N,N-Diisopropylethylamine, ReagentPlus®, ≥99%
Sigma-Aldrich
Aluminum oxide, nanopowder, <50 nm particle size (TEM)
Sigma-Aldrich
Aluminum oxide, nanopowder, 13 nm primary particle size (TEM), 99.8% trace metals basis
Sigma-Aldrich
2-Methylpyridine, Arxada quality, ≥99.0% (GC)
Sigma-Aldrich
Aluminum oxide, nanoparticles, 30-60 nm particle size (TEM), 20 wt. % in H2O
Sigma-Aldrich
Aluminum oxide, single crystal substrate, <0001>
Supelco
2-Picoline, analytical standard
Sigma-Aldrich
Aluminum oxide, activated, acidic, Brockmann I
Sigma-Aldrich
Toluene, ACS reagent, ≥99.5%
Sigma-Aldrich
Toluene, suitable for HPLC, 99.9%
Sigma-Aldrich
Aluminum oxide, powder, primarily α phase, ≤10 μm avg. part. size, 99.5% trace metals basis
Sigma-Aldrich
Aluminum oxide, Type WN-6, Neutral, Activity Grade Super I
Sigma-Aldrich
Toluene, Laboratory Reagent, ≥99.3%
Sigma-Aldrich
Toluene, ACS reagent, ≥99.5%
Sigma-Aldrich
Aluminum oxide, activated, neutral, Brockmann I
Sigma-Aldrich
Aluminum oxide, activated, basic, Brockmann I